CLGN stock icon

CollPlant Biotechnologies
CLGN

$4.87
4.51%
 

About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Employees: 73

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

0.13% less ownership

Funds ownership: 12.5% [Q4 2023] → 12.37% (-0.13%) [Q1 2024]

17% less capital invested

Capital invested by funds: $9.14M [Q4 2023] → $7.59M (-$1.55M) [Q1 2024]

24% less funds holding

Funds holding: 17 [Q4 2023] → 13 (-4) [Q1 2024]

67% less call options, than puts

Call options by funds: $1K | Put options by funds: $3K

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$11
126%
upside
Avg. target
$11
126%
upside
High target
$11
126%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
126%upside
$11
Buy
Reiterated
30 May 2024
HC Wainwright & Co.
Swayampakula Ramakanth
126%upside
$11
Buy
Reiterated
5 Apr 2024

Financial journalist opinion

Based on 3 articles about CLGN published over the past 30 days